Heat Biologics Partners with Waisman to Manufacture COVID-19 Vaccine

Wisconsin-based Waisman Biomanufacturing will produce the vaccine under development by Heat Biologics for the virus that causes COVID-19.

Golden pills arranged to spell out the word "SARS-CoV-2."

North Carolina-based biopharmaceutical company Heat Biologics (NASDAQ: HTBX) has announced that their COVID-19 vaccine will be produced in collaboration with Waisman Biomanufacturing, a biologics and cell therapy manufacturer associated with the University of Wisconsin.

Chief Executive Officer of Heat Biologics Jeff Wolf stated, “We continue to advance our COVID-19 vaccine and are pleased to be working with Waisman to assist our manufacturing efforts. We remain encouraged by the potential of our platform to provide broad protection against COVID-19, particularly for elderly patients and those with underlying health conditions that have an increased risk of complications and death from COVID-19.”

“Our confidence is reinforced by numerous National Institutes of Health (NIH) and U.S. Department of Defense (DOD)-funded mice and primate trials utilizing our gp96 platform to generate vaccines against SIV/HIV, malaria, zika and other infectious diseases. These trials have demonstrated gp96 is a powerful platform with antiviral activity in the lungs, as evidenced by a potent immune response and effectiveness in the induction of mucosal immunity in several infectious disease models,” Mr. Wolf continued.

Related:  Moderna COVID-19 Vaccine: Top 5 Things to Know and Latest Updates

Managing Director of Waisman Biomanufacturing Carl Ross stated, “We are honored to partner with Heat again on the development of this very unique COVID-19 approach. We believe our unique capabilities and expertise, as well as the experience that we gained working with Heat to manufacture their HS-130, which is based upon the same gp96 platform, will help further the manufacturing timeline for this potentially life-saving COVID-19 vaccine.”

Waisman Biomanufacturing previously produced HS-130, Heat Biologic’s cell therapy engineered to express the ligand of the OX40 receptor, a pro-inflammatory cell surface protein that stimulates the anti-cancer response of T lymphocytes. HS-130 is currently being evaluated for the treatment of solid tumors in a phase 1 human clinical trial.

Stay aware of the latest immunology and immune-biotech news by subscribing to our newsletter.

Heat Biologic’s COVID-19 vaccine, which is being developed in collaboration with scientists at the University of Miami, is intended to induce both a T cell and neutralizing antibody response against the SARS-CoV-2 coronavirus.

Related:  Biocept Reports Publication Further Validating Cancer-Detecting Liquid Biopsy Platform

Multiple COVID-19 vaccines are currently under development including Novavax’s candidate NVX-CoV-2373, which recently advanced to Phase 1/2 human clinical trials.